We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-3.36%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$5.73B
AUM Growth
-$1.02B
Cap. Flow
-$157M
Cap. Flow %
-2.73%
Top 10 Hldgs %
44.42%
Holding
91
New
5
Increased
15
Reduced
36
Closed
16
Avg Time Held
7.2 quarters
Top 10 Avg Time Held
7.5 quarters
Top 20 Avg Time Held
5.5 quarters

Top Buys

Rank Stock Value
1
ABSI icon
Absci
ABSI
+$156M
2
IVVD icon
Invivyd
IVVD
+$121M
3
LIVN icon
LivaNova
LIVN
+$88.7M
4
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$44.8M
5
STVN icon
Stevanato
STVN
+$28M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$98.4M
2
ZY
Zymergen Inc. Common Stock
ZY
+$60.9M
3
SLQT icon
SelectQuote
SLQT
+$46.5M
4
CRL icon
Charles River Laboratories
CRL
+$40.1M
5
CI icon
Cigna
CI
+$37.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.61%
2 Consumer Staples 3.39%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FATE icon
1
Fate Therapeutics
FATE
$230M
$768M 13.39%
12,957,222
– –
2015 Q2
25 quarters
ALLK icon
2
DELISTED
Allakos
ALLK
$226M 3.94%
2,131,796
-85,200
-4% -$7.61M
2018 Q3
12 quarters
IGMS icon
3
DELISTED
IGM Biosciences
IGMS
$225M 3.93%
3,425,455
– –
2019 Q3
8 quarters
ARGX icon
4
argenx
ARGX
$51.9B
$221M 3.85%
730,582
-59,700
-8% -$18.9M
2017 Q4
15 quarters
ADCT icon
5
ADC Therapeutics
ADCT
$189M
$204M 3.57%
7,529,329
+7,300
+0.1% +$187K
2020 Q2
5 quarters
FOLD icon
6
DELISTED
Amicus Therapeutics
FOLD
$199M 3.46%
20,799,303
– –
2013 Q2
33 quarters
SKIN icon
7
SkinHealth Systems
SKIN
$75.2M
$194M 3.39%
374,185
+56,523
+18% +$24.9M
2020 Q4
3 quarters
LIVN icon
8
LivaNova
LIVN
$4.17B
$174M 3.03%
2,191,019
+1,079,335
+97% +$88.7M
2021 Q1
2 quarters
BEAM icon
9
Beam Therapeutics
BEAM
$2.43B
$172M 3%
1,975,006
-77,500
-4% -$7.79M
2020 Q1
6 quarters
CLDX icon
10
Celldex Therapeutics
CLDX
$2.19B
$164M 2.87%
3,043,298
+31,217
+1% +$1.46M
2020 Q2
5 quarters
KYMR icon
11
Kymera Therapeutics
KYMR
$8.85B
$164M 2.86%
2,793,708
+262,200
+10% +$15.2M
2020 Q3
4 quarters
NVTA
12
DELISTED
Invitae Corporation
NVTA
$151M 2.64%
5,317,477
+670,084
+14% +$19.6M
2020 Q2
5 quarters
IVVD icon
13
Invivyd
IVVD
$181M
$137M 2.39%
+3,246,960
New +$121M
2021 Q3
0 quarters
DCPH icon
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$137M 2.39%
4,031,521
-213,200
-5% -$6.8M
2017 Q3
16 quarters
REPL icon
15
Replimune Group
REPL
$1.1B
$121M 2.11%
4,078,112
-113,400
-3% -$3.68M
2018 Q3
12 quarters
ATRA icon
16
Atara Biotherapeutics
ATRA
$94.5M
$116M 2.02%
258,651
+668
+0.3% +$239K
2014 Q4
27 quarters
STTK icon
17
Shattuck Labs
STTK
$536M
$115M 2%
5,619,914
– –
2020 Q4
3 quarters
JAZZ icon
18
Jazz Pharmaceuticals
JAZZ
$13.8B
$112M 1.96%
861,401
+1,300
+0.2% +$196K
2021 Q1
2 quarters
KRYS icon
19
Krystal Biotech
KRYS
$9.56B
$104M 1.81%
1,982,432
-89,700
-4% -$5.31M
2018 Q4
11 quarters
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
$99.7M 1.74%
587,374
-184,011
-24% -$28.6M
2021 Q1
2 quarters
ABSI icon
21
Absci
ABSI
$1.52B
$93.4M 1.63%
+8,031,094
New +$156M
2021 Q3
0 quarters
NRIX icon
22
Nurix Therapeutics
NRIX
$2.59B
$92.7M 1.62%
3,093,077
-97,000
-3% -$2.99M
2020 Q3
4 quarters
VERV icon
23
DELISTED
Verve Therapeutics
VERV
$87.8M 1.53%
1,869,030
-67,500
-3% -$3.97M
2021 Q2
1 quarter
SRRK icon
24
Scholar Rock
SRRK
$4.8B
$84.2M 1.47%
2,550,205
+243,177
+11% +$8.51M
2018 Q2
13 quarters
RGNX icon
25
Regenxbio
RGNX
$459M
$84.2M 1.47%
2,008,001
-130,200
-6% -$4.68M
2017 Q1
18 quarters
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2021 Portfolio in Review

As of Q3 2021, Redmile Group held 91 positions worth $5.73B, down 15% from $6.76B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group's Q3 2021 filing shows 5 new, 15 increased, 36 reduced and 16 closed positions. Its largest new stake was Absci: 8,031,094 shares worth $93.4M. The largest sale was DexCom, an estimated $98.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Financials.

  • Redmile Group's largest Q3 2021 buy was Absci: 8,031,094 shares worth $93.4M.
  • Redmile Group added most to LivaNova in Q3 2021, an estimated $88.7M increase.
  • Redmile Group's biggest Q3 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $28.6M.
  • Redmile Group fully exited DexCom in Q3 2021, selling an estimated $98.4M.
  • Redmile Group's ten largest holdings make up 44% of its $5.73B portfolio in Q3 2021.
  • Redmile Group opened 5 new positions and closed 16 in Q3 2021.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $5.73B.

Based on Redmile Group's 13F filing for Q3 2021, filed 15 Nov 2021.